Janux Therapeutics, Inc. (JANX) shareholders
Close on Nov 17, 2026Market cap $654.78MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (19.90%), Rajeev Shah (19.90%) and 1 more | 11,971,377 | 19.90% | 13D (active) amendment | Mar 6, 2025 |
| Janus Henderson Group PLC | 4,196,409 | 6.90% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 4,098,457 | 6.70% | 13G (passive) amendment | Jun 30, 2026 |
| W. Lawrence Hawkins Joint filing with Prosight Management, LP (5.20%), Prosight Partners, LLC (5.20%) | 3,157,220 | 5.30% | 13G (passive) | Feb 3, 2026 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (5.00%), Point72 Capital Advisors, Inc. (5.00%) | 3,069,759 | 5.00% | 13G (passive) | Apr 28, 2026 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (5.31%), Phillip Gross (5.31%) | 3,061,750 | 5.31% | 13G (passive) | Dec 31, 2024 |
| Bregua Corporation | 2,999,990 | 5.80% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JANX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 11,189,693 | 18.30% | $171.87M | – | 1.49% |
| BlackRock, Inc. | 6,134,667 | 10.03% | $94.23M | +701,434 | 0.00% |
| Prosight Management, LP | 3,804,481 | 6.22% | $58.44M | +254,481 | 10.07% |
| State Street Corp | 3,004,899 | 4.92% | $46.16M | +540,882 | 0.00% |
| FMR LLC | 2,412,825 | 3.95% | $37.06M | −122,899 | 0.00% |
| Federated Hermes, Inc. | 2,352,927 | 3.85% | $36.14M | +2,298,727 | 0.05% |
| Point72 Asset Management, L.P. | 1,993,837 | 3.26% | $30.63M | +837,697 | 0.03% |
| Vanguard Capital Management LLC | 1,857,351 | 3.04% | $28.53M | +45,986 | 0.00% |
| TCG Crossover Management, LLC | 1,789,617 | 2.93% | $27.49M | – | 0.66% |
| Alyeska Investment Group, L.P. | 1,647,140 | 2.69% | $25.30M | +46,051 | 0.07% |
| Nantahala Capital Management, LLC | 1,619,828 | 2.65% | $24.88M | +809,914 | 0.41% |
| Wellington Management Group Llp | 1,507,360 | 2.47% | $23.15M | −90,290 | 0.00% |
| Vanguard Portfolio Management LLC | 1,330,710 | 2.18% | $20.44M | +40,454 | 0.00% |
| Two Sigma Investments, LP | 1,207,250 | 1.97% | $18.54M | +1,091,151 | 0.01% |
| Geode Capital Management, LLC | 1,204,150 | 1.97% | $18.50M | +57,426 | 0.00% |
| Citadel Advisors LLC | 1,200,737 | 1.96% | $18.44M | +848,560 | 0.00% |
| Algert Global LLC | 1,110,889 | 1.82% | $17.06M | +667,492 | 0.20% |
| D. E. Shaw & Co., Inc. | 1,096,509 | 1.79% | $16.84M | +998,114 | 0.01% |
| Goldman Sachs Group Inc | 952,675 | 1.56% | $14.63M | +350,662 | 0.00% |
| Bank Of America Corp /De/ | 910,460 | 1.49% | $13.98M | +108,814 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 198 | 62M | 100.0% | 41 / 84 | 45 / 30 | 13M | 7M |
| Q1 2026 | 190 | 60M | 97.5% | 46 / 66 | 54 / 29 | 13M | 13M |
| Q4 2025 | 176 | 62M | 100.0% | 44 / 69 | 41 / 38 | 16M | 19M |
| Q3 2025 | 174 | 65M | 100.0% | 22 / 58 | 63 / 22 | 7M | 7M |
| Q2 2025 | 174 | 66M | 100.0% | 16 / 80 | 54 / 22 | 8M | 8M |
| Q1 2025 | 182 | 67M | 100.0% | 19 / 96 | 44 / 52 | 9M | 7M |
| Q4 2024 | 216 | 64M | 100.0% | 78 / 80 | 43 / 21 | 21M | 2M |
| Q3 2024 | 160 | 46M | 74.7% | 33 / 53 | 51 / 27 | 8M | 7M |
| Q2 2024 | 155 | 46M | 75.6% | 55 / 58 | 33 / 19 | 11M | 8M |
| Q1 2024 | 121 | 43M | 70.6% | 63 / 25 | 28 / 6 | 13M | 3M |
| Q4 2023 | 64 | 34M | 55.0% | 14 / 27 | 11 / 7 | 1M | 3M |
| Q3 2023 | 57 | 35M | 57.4% | 9 / 23 | 16 / 6 | 5M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
186 funds held JANX in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of JANX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,928,491 | 3.15% | $29.62M | 0.28% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 1,374,115 | 2.25% | $20.85M | 0.93% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,263,837 | 2.07% | $19.41M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,127,776 | 1.84% | $17.32M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 552,368 | 0.90% | $8.48M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 471,460 | 0.77% | $7.15M | 0.02% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 423,646 | 0.69% | $6.51M | 0.05% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 405,417 | 0.66% | $6.23M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 403,672 | 0.66% | $6.20M | 0.07% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 381,000 | 0.62% | $5.78M | 0.14% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 380,620 | 0.62% | $5.55M | 0.11% | May 29, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 376,425 | 0.62% | $5.71M | 0.68% | Jul 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 340,741 | 0.56% | $5.23M | 0.05% | Jun 30, 2026 |
| Fidelity Series Small Cap Core Fund | 328,500 | 0.54% | $4.98M | 0.32% | Jul 31, 2026 |
| Vanguard Explorer Fund | 326,362 | 0.53% | $4.95M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Alan Campbell | President and CEO, Director | 264,742 | 0.43% | Jul 31, 2026 |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | 75,941 | 0.12% | Jun 4, 2026 |
| Maria Dobek | Vice President, Accounting | 32,270 | 0.05% | May 13, 2026 |
| William Go | Chief Medical Officer | 44,000 | 0.07% | Feb 4, 2026 |
| Andrew Hollman Meyer | Chief Business Officer | 83,095 | 0.14% | Jan 2, 2026 |
| Charles M. Winter | Chief Technical Officer | 77,721 | 0.13% | Jan 2, 2026 |
| Thomas DiRaimondo | Chief Scientific Officer | 155,825 | 0.25% | Jan 2, 2026 |
| Zachariah McIver | Chief Medical Officer | 23,286 | 0.04% | Jan 2, 2026 |
| Byron Robinson | Chief Strategy Officer | 28,000 | 0.05% | Jan 3, 2025 |
| Vickie L. Capps | Director | 79,598 | 0.13% | Jun 12, 2026 |
| Jake Simson | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 6,250 | 0.01% | Jun 12, 2026 |
| Ronald W. Barrett | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Eric Dobmeier | Director | 15,481 | 0.03% | Jun 12, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Winston Kung | Director | 11,750 | 0.02% | Jun 12, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 12, 2026 |
| Peter Kolchinsky | Director, 10% owner | 9,317,246 | 15.24% | Jun 12, 2026 |
| Natasha Hernday | Director | 15,481 | 0.03% | Jun 12, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 2,500 | 0.00% | Jun 12, 2026 |
| Alana B. McNulty | Director | 6,250 | 0.01% | Jun 13, 2025 |
| Sheila Gujrathi | Director | 118,889 | 0.19% | Jun 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Alan Campbell President and CEO, Director | Jul 31, 2026 | Gift | −123,840 | – | – | 264,742 |
| David Alan Campbell President and CEO, Director | Jul 8, 2026 | Option exercise | +7,000 | $4.21 | $29.47K | 388,582 |
| Jake Simson Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| Winston Kung Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| RA Capital Nexus Fund II, L.P. Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| Vickie L. Capps Director | Jun 11, 2026 | Award | +5,500 | – | – | 79,598 |
| Eric Dobmeier Director | Jun 11, 2026 | Award | +5,500 | – | – | 15,481 |
| Natasha Hernday Director | Jun 11, 2026 | Award | +5,500 | – | – | 15,481 |
| Ronald W. Barrett Director | Jun 11, 2026 | Award | +5,500 | – | – | 11,750 |
| Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr | Jun 2, 2026 | Sale | −4,059 | $14.03 | $56.95K | 75,941 |
| Maria Dobek Vice President, Accounting | May 11, 2026 | Sale | −2,038 | $14.17 | $28.88K | 32,270 |
| William Go Chief Medical Officer | Feb 2, 2026 | Award | +44,000 | – | – | 44,000 |
| Maria Dobek Vice President, Accounting | Jan 2, 2026 | Sale | −1,462 | $13.73 | $20.07K | 15,373 |
| Maria Dobek Vice President, Accounting | Jan 2, 2026 | Award | +18,935 | – | – | 34,308 |
| Andrew Hollman Meyer Chief Business Officer | Jan 2, 2026 | Sale | −1,879 | $13.73 | $25.80K | 83,095 |
| David Alan Campbell President and CEO, Director | Jan 2, 2026 | Sale | −8,072 | $13.73 | $110.83K | 284,982 |
| David Alan Campbell President and CEO, Director | Jan 2, 2026 | Award | +96,600 | – | – | 381,582 |
| Charles M. Winter Chief Technical Officer | Jan 2, 2026 | Sale | −2,401 | $13.73 | $32.97K | 77,721 |
| Charles M. Winter Chief Technical Officer | Jan 2, 2026 | Award | +28,600 | – | – | 106,321 |
| Zachariah McIver Chief Medical Officer | Jan 2, 2026 | Sale | −2,714 | $13.73 | $37.26K | 23,286 |
| Zachariah McIver Chief Medical Officer | Jan 2, 2026 | Award | +29,000 | – | – | 52,286 |
| Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr | Jan 2, 2026 | Award | +36,000 | – | – | 80,000 |
| Thomas DiRaimondo Chief Scientific Officer | Jan 2, 2026 | Award | +31,400 | – | – | 155,825 |
| Thomas DiRaimondo Chief Scientific Officer | Jan 2, 2026 | Sale | −2,505 | $13.73 | $34.39K | 124,425 |
| Andrew Hollman Meyer Chief Business Officer | Dec 1, 2025 | Option exercise | +3,333 | $10.59 | $35.30K | 88,307 |
| Andrew Hollman Meyer Chief Business Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −2,700 | $32.85 | $88.70K | 85,607 |
| Andrew Hollman Meyer Chief Business Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −633 | $33.52 | $21.22K | 84,974 |
| Andrew Hollman Meyer Chief Business Officer | Nov 14, 2025 | Option exercise | +3,333 | $10.59 | $35.30K | 88,307 |
| Andrew Hollman Meyer Chief Business Officer | Nov 14, 2025 | Sale(10b5-1 plan) | −3,333 | $30.00 | $99.99K | 84,974 |
| Andrew Hollman Meyer Chief Business Officer | Oct 28, 2025 | Option exercise | +6,666 | $10.59 | $70.59K | 98,804 |
| Andrew Hollman Meyer Chief Business Officer | Oct 28, 2025 | Option exercise | +9,999 | $4.21 | $42.10K | 92,138 |
| Andrew Hollman Meyer Chief Business Officer | Oct 28, 2025 | Sale(10b5-1 plan) | −16,665 | $30.06 | $500.95K | 82,139 |
| Eric Dobmeier Director | Jun 11, 2025 | Award | +3,750 | – | – | 9,981 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Winston Kung Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Jake Simson Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Sheila Gujrathi Director | Jun 11, 2025 | Award | +3,750 | – | – | 118,889 |
| Natasha Hernday Director | Jun 11, 2025 | Award | +3,750 | – | – | 8,731 |
| Ronald W. Barrett Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Alana B. McNulty Director | Jun 11, 2025 | Award | +3,750 | – | – | 6,250 |
| Vickie L. Capps Director | Jun 11, 2025 | Award | +3,750 | – | – | 74,098 |
| Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr | Jun 2, 2025 | Award | +44,000 | – | – | 44,000 |
| Andrew Hollman Meyer Chief Business Officer | May 1, 2025 | Option exercise | +3,333 | $4.21 | $14.03K | 85,472 |
| Andrew Hollman Meyer Chief Business Officer | May 1, 2025 | Sale(10b5-1 plan) | −2,933 | $31.95 | $93.71K | 82,539 |
| Andrew Hollman Meyer Chief Business Officer | May 1, 2025 | Sale(10b5-1 plan) | −400 | $32.60 | $13.04K | 82,139 |
| Andrew Hollman Meyer Chief Business Officer | Apr 21, 2025 | Option exercise | +3,334 | $4.21 | $14.04K | 85,473 |
| Andrew Hollman Meyer Chief Business Officer | Apr 21, 2025 | Sale(10b5-1 plan) | −3,334 | $30.00 | $100.02K | 82,139 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 7, 2025 | Buy | +110,206 | $31.02 | $3.42M | 10,141,287 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 6, 2025 | Buy | +372,093 | $30.78 | $11.45M | 10,031,081 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 5, 2025 | Buy | +37,455 | $31.30 | $1.17M | 9,658,988 |
| Capital Healthcare Fund LP RA Director, 10% owner | Mar 5, 2025 | Buy | +304,287 | $30.56 | $9.30M | 9,621,533 |
| Andrew Hollman Meyer Chief Business Officer | Mar 3, 2025 | Sale(10b5-1 plan) | −2,433 | $31.88 | $77.56K | 83,040 |
| Andrew Hollman Meyer Chief Business Officer | Mar 3, 2025 | Sale(10b5-1 plan) | −901 | $32.85 | $29.60K | 82,139 |
| Andrew Hollman Meyer Chief Business Officer | Mar 3, 2025 | Option exercise | +3,334 | $4.21 | $14.04K | 85,473 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Option exercise | +3,334 | $4.21 | $14.04K | 85,473 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −2,418 | $42.08 | $101.75K | 83,055 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −816 | $42.77 | $34.90K | 82,239 |
| Andrew Hollman Meyer Chief Business Officer | Feb 3, 2025 | Sale(10b5-1 plan) | −100 | $43.60 | $4.36K | 82,139 |
| David Alan Campbell President and CEO, Director | Jan 7, 2025 | Sale(10b5-1 plan) | −5,000 | $60.00 | $300.00K | 293,054 |
| Andrew Hollman Meyer Chief Business Officer | Jan 2, 2025 | Sale(10b5-1 plan) | −200 | $57.37 | $11.47K | 82,139 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Janux Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 18,477 shares on Sep 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Janeen Noel Doyle Officer | Jun 2, 2026 | 4,059 | $56.94K | Jun 2, 2026 | Restricted Stock Units vesting under registered plan |
| Andy Meyer Former Affiliate | Apr 13, 2026 | 1,877 | $28.25K | Apr 13, 2026 | Exercise of options under a registered plan |
| Zachariah McIver Former Officer | Apr 2, 2026 | 74,802 | $1.10M | Apr 2, 2026 | Exercise of options under a registered plan |
| Andy Meyer Former Affiliate | Jan 26, 2026 | 178,767 | $2.60M | Jan 26, 2026 | Exercise of options under a registered plan |
| Andy Meyer Former Affiliate | Jan 23, 2026 | 118,122 | $1.74M | Jan 23, 2026 | Exercise of options under a registered plan |
| Byron Robinson Officer | Dec 15, 2025 | 16,666 | $258.37K | Dec 15, 2025 | Stock Option Exercise |
| Byron Robinson Officer | Dec 8, 2025 | 50,000 | $826.00K | Dec 8, 2025 | Stock Option Exercise |
| Byron Robinson Officer | Dec 2, 2025 | 63,125 | $1.03M | Dec 2, 2025 | Stock Option Exercise |
| Andrew Hollman Meyer Officer | Dec 1, 2025 | 3,333 | $113.62K | Dec 1, 2025 | Exercise of Stock Options |
| Andrew Hollman Meyer Officer | Nov 14, 2025 | 3,333 | $91.52K | Nov 14, 2025 | Exercise of Stock Options |
| Andrew Hollman Meyer Officer | Oct 28, 2025 | 16,665 | $455.79K | Oct 28, 2025 | Exercise of Stock Options |
| Andrew Hollman Meyer Officer | May 1, 2025 | 3,333 | $110.66K | May 1, 2025 | Exercise of Stock Options |
| Andrew Hollman Meyer Officer | Apr 21, 2025 | 3,334 | $98.99K | Apr 21, 2025 | Exercise of Stock Options |
| Andrew Hollman Meyer Officer | Mar 3, 2025 | 3,334 | $109.66K | Mar 3, 2025 | Exercise of Stock Options |
| Andrew Hollman Meyer Officer | Feb 3, 2025 | 3,334 | $144.96K | Feb 3, 2025 | Exercise of Stock Options |
See a number that looks wrong?